FINAL PROGR AM - American Society of Gene & Cell Therapy

More documents

Recommendations

Info

AMERICAN SOCIETY OF GENE THERAPY • Final Program 19 FACULTY LIST Christof von Kalle, MD Cincinnati Children’s Hospital Research Foundation Cincinnati, Ohio Dorothee Von Laer, MD Georg Speyer Haus Frankfurt, Germany Ernst Wagner, PhD University of Munich Munich, Germany Britta Elisabeth Wahren, MD, PhD Swedish Institute for Infectious Disease Control Stockholm, Sweden David B. Weiner, PhD University of Pennsylvania Philadelphia, Pennsylvania Daniel Weiss, MD, PhD University of Vermont College of Medicine Burlington, Vermont Bryan Williams, PhD The Cleveland Clinic Foundation Cleveland, Ohio Carolyn Wilson, PhD Food and Drug Administration Bethesda, Maryland James M. Wilson, MD, PhD University of Pennsylvania School of Medicine Philadelphia, Pennsylvania William S. M. Wold, PhD St. Louis University School of Medicine St. Louis, Missouri John H. Wolfe, VMD, PhD The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania Jon Wolff, MD University of Wisconsin Madison Madison, Wisconsin Savio L.C. Woo, PhD Mount Sinai School of Medicine New York, New York Peter K. Working, PhD, DABT Cell Genesys, Incorporated South San Francisco, California Xiao Xiao, PhD University of Pittsburgh Pittsburgh, Pennsylvania Ning-Sun Yang, PhD Inst of BioAgricultural Sciences Academia Sinica Taipei, Taiwan Mervin Yoder, MD Cancer Research Institute Indianapolis, Indiana Patricia Yotnda, PhD Baylor College of Medicine Houston, Texas Hua Yu, PhD H. Lee Moffitt Cancer Center Tampa, Florida John A. Zaia, MD City of Hope National Medical Center Duarte, California Steven J. Zullo, PhD National Institutes of Health Bethesda, Maryland
20 8th Annual Meeting • June 1 - 5, 2005 • St. Louis GENERAL MEETING INFORMATION AMERICAN SOCIETY OF GENE THERAPY MISSION AND GOALS The American Society of Gene Therapy (ASGT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene and related cell and nucleic acid therapies and the promotion of professional and public education in the field. ASGT is the largest medical professional organization representing researchers and scientists dedicated to discovering new gene therapies. ASGT was established in 1996, and has grown to close to 3,000 members from around the world. ASGT is committed to: · Promoting Research, Development and Application · Exchanging Information and Promote Education Among Professionals and the Public · Promoting Development of Clinical Translations The ASGT 8th Annual Meeting will serve as a comprehensive forum to achieve these goals. NEEDS Clinical gene transfer has become more and more complex due to ongoing developments in the fields of gene therapy itself, together with bioethics, research integrity, and financial conflicts, as well as new federal mandates, regulations and guidelines. Oligonucleotide Based Therapies, RNAi and Vaccine Therapies will also be discussed as well as many other topics. This meeting will provide an educational forum for scientists and clinicians to expand their knowledge about the broad developments in these fields. EDUCATIONAL OBJECTIVES At the conclusion of the activity, the participant should be able to: · Discuss key aspects of the current laboratory and/or clinical research in gene therapy. · Demonstrate knowledge of methods being used by gene therapy researchers and practitioners. · Describe one or more stimulating new areas of inquiry in the area of gene therapy. · Demonstrate familiarity with federal regulations and guidelines for clinical gene transfer studies. EDUCATIONAL METHODS AND MATERIALS Lectures, Case Presentations, Panel Discussions, Question and Answer Sessions, Workshops, Audio/Video Presentations, Abstracts, Posters, Executive Summary. TARGET AUDIENCE The target audience includes basic science and translational researchers, clinical investigators, physicians, industry executives and scientists, postdoctoral fellows, graduate students, employees of federal government and regulatory agencies, and other healthcare professionals with an interest in the latest advancements in the field of gene therapy. EVALUATION METHOD Evaluation by questionnaire will address program content, presentation, and possible bias. Please take time to complete the evaluation forms distributed at each session you attend. Your input and comments are essential in planning future educational sessions. When completed, evaluations can be returned to the ushers assigned to your session or dropped in the evaluation collection boxes located throughout America’s Center. ACCREDITATION/CREDIT DESIGNATION This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Stanford University School of Medicine and the American Society of Gene Therapy. Stanford University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Stanford University School of Medicine designates this educational activity for a maximum of 31 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity. DISCLOSURE It is the policy of Stanford University that the provider and faculty/presenters disclose any significant financial or other relationships with commercial companies whose products may be discussed in the activity, or the commercial supporters, if any. Stanford University also requires that faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Faculty, topics, program schedule, and credit are subject to change. CME CERTIFICATES CME Certificates will be available at the CME desk for participants requiring CME credit for this meeting.
Page 1 and 2: AMERICAN SOCIETY OF GENE THERAPY 8t
Page 3 and 4: 2 8th Annual Meeting • June 1 - 5
Page 11 and 12: 10 8th Annual Meeting • June 1 -
Page 19: 18 8th Annual Meeting • June 1 -
Page 71 and 72:
70 8th Annual Meeting • June 1 -
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
156 NOTES 8th Annual Meeting • Ju
show all

FINAL PROGR AM - American Society of Gene & Cell Therapy

Create successful ePaper yourself

Delete template?

Save as template?